>
Switch to:

Turning Point Therapeutics EV-to-Revenue

: 42.43 (As of Today)
View and export this data going back to 2019. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Turning Point Therapeutics's enterprise value is $2,129.96 Mil. Turning Point Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 was $50.21 Mil. Therefore, Turning Point Therapeutics's EV-to-Revenue for today is 42.43.

NAS:TPTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 41.15   Med: 145.69   Max: 204.52
Current: 85.19

41.15
204.52

During the past 4 years, the highest EV-to-Revenue of Turning Point Therapeutics was 204.52. The lowest was 41.15. And the median was 145.69.

NAS:TPTX's EV-to-Revenue is ranked lower than
72% of the 925 Companies
in the Biotechnology industry.

( Industry Median: 20.64 vs. NAS:TPTX: 85.19 )

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2021-05-12), Turning Point Therapeutics's stock price is $65.94. Turning Point Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $1.11. Therefore, Turning Point Therapeutics's PS Ratio for today is 59.51.


Turning Point Therapeutics EV-to-Revenue Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Annual Data
Dec17 Dec18 Dec19 Dec20
EV-to-Revenue - - - 192.51

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 119.22 192.51 70.47

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Turning Point Therapeutics EV-to-Revenue Distribution

* The bar in red indicates where Turning Point Therapeutics's EV-to-Revenue falls into.



Turning Point Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Turning Point Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2129.962/50.205
=42.43

Turning Point Therapeutics's current Enterprise Value is $2,129.96 Mil.
Turning Point Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 was 0 (Jun. 2020 ) + 25 (Sep. 2020 ) + 0 (Dec. 2020 ) + 25.205 (Mar. 2021 ) = $50.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics  (NAS:TPTX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Turning Point Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=65.94/1.108
=59.51

Turning Point Therapeutics's share price for today is $65.94.
Turning Point Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was 0 (Jun. 2020 ) + 0.593 (Sep. 2020 ) + 0 (Dec. 2020 ) + 0.515 (Mar. 2021 ) = $1.11.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics EV-to-Revenue Related Terms


Turning Point Therapeutics EV-to-Revenue Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)